Results 51 to 60 of about 6,218 (156)

Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study

Viruses
This study investigates the intricate interplay between Metabolic-associated Fatty Liver Disease (MAFLD) and COVID-19, exploring the impact of MAFLD on disease severity, outcomes, and the efficacy of the antiviral agent Paxlovid (nirmatrelvir/ritonavir).
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, Oleksandr Kamyshnyi   +3 more
doaj   +1 more source

Coronavirus M Protein Hijacks Toll‐Interacting Protein (TOLLIP) to Suppress NF‐κB Signaling and Promote Immune Evasion

MedComm, Volume 7, Issue 7, July 2026.
Under physiological conditions, pathogenic stimuli activate TLR/IL1‐R signaling, triggering TOLLIP dissociation from IRAK1 and subsequent IRAK1 phosphorylation, TRAF6 ubiquitination, and NF‐κB activation. During SARS‐CoV‐2 infection, viral M protein binds TOLLIP and stabilizes the TOLLIP–IRAK1 complex, thereby suppressing NF‐κB signaling, impairing ...
Yabin Zhang, Lu Kang, Yu Zhong, Songjun Shao, Senren Xue, Changliang Liu, Xiaoqi Zheng, Jing‐Wen Lin, Yu Chen, Fengming Luo, Huajing Wan   +10 more
wiley   +1 more source

Human Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
Anuradha Ramamoorthy, Alana Chen, Edwin Chiu Yuen Chow, Daphne Guinn, Anjali Iyer, Sonia Pahwa, Yunzhao Ren, Chinmay Shukla, Suresh Doddapaneni, Zhixia Yan Danielsen   +9 more
wiley   +1 more source

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study [PDF]

Osong Public Health and Research Perspectives
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older.
Dong-Hwi Kim, Min-Gyu Yoo, Na-Young Kim, So Young Choi, Minjeong Jang, Misuk An, Se-Jin Jeong, Jungyeon Kim   +7 more
doaj   +1 more source

Drug-related problems and challenges encountered by pharmacists in nirmatrelvir/ritonavir counselling during the covid-19 pandemic: a multi-center study

Scientific Reports
Pharmacists’ counselling roles expanded significantly during the COVID-19 pandemic, yet drug-related problems (DRPs) and challenges during nirmatrelvir/ritonavir counselling remain underreported.
Shamala Balan, Kavidha Mohan, Vanitha Hong Wee Liang, Hanis Hazwanie Ghazali, Chew Li Suan, Chong Chia Chee, Kong Wei En, Leana Fatimah Makhdzir, Nurul Syafiqah Samsuri, Nor Mazni Mohamad Tamyes, Juliana Nazlim Lim, Nur Amirah Mohd Noor Azami, Suhaili Samad, Kiren Kaur Chut Singh, Nurfareeza Nazir Khan, Siti Hajar Chamati, Nurdiana Hassan, Kuay Hue Ping, Farraha Nordin, Lau Wai Hoong, Azlen Awatif Abu Bakar   +20 more
doaj   +1 more source

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients

Scientific Reports
Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain.
Fatemeh Saheb Sharif-Askari, Hawra Ali Hussain Alsayed, Narjes Saheb Sharif-Askari, Ali Al Sayed Hussain, Saleh Al-Muhsen, Rabih Halwani   +5 more
doaj   +1 more source

A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient

Journal of Cardiothoracic Surgery
Background Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients.
Chien-Ming Lo, Wei-Hsun Chen, Meng-Yun Tsai, Hung-I Lu, Yu-Hsin Hsiao, Kai-Hao Chuang, Yu Chen, Hsuan-Feng Wu, Kuo-Tung Huang, Yi-Hsi Wang   +9 more
doaj   +1 more source

Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation

Nature Communications
Currently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection.
Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Sophelia H. S. Chan, Eric H. Y. Lau, Benjamin J. Cowling, Gabriel M. Leung   +6 more
doaj   +1 more source

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj  

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

Drugs - Real World Outcomes
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir ...
Ee Vien Low, Hoon Shien Teh, Nicholas Yee Liang Hing, Suresh Kumar Chidambaram, Mohan Dass Pathmanathan, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +14 more
doaj   +1 more source